title: [On rationality of total mesorectal excision for rectal cancer].
abstract: OBJECTIVE
  To discuss the rationality and clinical significance of total mesorectal excision (TME) assessed by the pattern of local recurrence of rectal cancer.
  
  
  METHODS
  207 rectal cancer patients treated by surgery from 1975 to 2001 who developed local recurrence were retrospectively studied as to the option of treatment based on their outcome. 172 of these 207 patients had complete record of follow-up with a follow-up rate of 83.0%.
  
  
  RESULTS
  The local recurrent sites of 207 patients were: anastomotic stoma 71, mesorectum 65, perineum 50, lymph nodes 59, multiple recurrences 89 and others sites rare. Among 81 patients who had been first treated by anterior resection (AR), 58 were again treated by abdomino-perineal resection (APR). Among 102 patients who had been treated by APR, 38 were treated by perineal tumor resection, 15 were treated by total and posterior pelvic organ resection, and 18 were supplemented with lymph node resection. By all modalities, the resection rate was 66.1% (137/207), in which the curable resection rate was 46% (63/137). The 5-year survival rate of patients with tumor resection was 23.3% (32/137), those treated by curable resection was 34.9% (22/63).
  
  
  CONCLUSIONS
  From the pattern of local recurrence, the operation for middle-lower rectal cancer must follow the principle of total mesorectum excision (TME). Patients with local recurrence should be energetically treated in the second operation if tolerable.
authors.affiliation: Department of General Surgery, Third Hospital, Harbin Medical University, Harbin 150040, China.
authors.forename: Xin-shu
authors.initials: XS
authors.lastname: Dong
authors.forename: Peng
authors.initials: P
authors.lastname: Zhao
authors.forename: Zhi-wei
authors.initials: ZW
authors.lastname: Yu
authors.forename: Ming
authors.initials: M
authors.lastname: Liu
authors.forename: Hai-tao
authors.initials: HT
authors.lastname: Xu
mesh_terms: D000230:Adenocarcinoma / Q000556:secondary / Q000601:surgery; D002288:Adenocarcinoma, Mucinous / Q000556:secondary / Q000601:surgery*; D000714:Anastomosis, Surgical; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D009364:Neoplasm Recurrence, Local / Q000601:surgery*; D009367:Neoplasm Staging; D012004:Rectal Neoplasms / Q000473:pathology / Q000601:surgery*; D012007:Rectum / Q000601:surgery*; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome